Vertex Pharmaceuticals (VRTX) Profit After Tax Growth (3y) (2012 - 2026)
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) Profit After Tax Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 91.31% |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 17.25% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 37.89% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 37.44% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -38.56% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 59.34% |
| 10 | Incyte | 25.61 Bn | 21.07 Bn | 1.57 Bn | 42.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.30% |
| Mar 31, 2026 | 13.80% |
| Dec 31, 2025 | 13.30% |
| Sep 30, 2025 | 5.19% |
| Jun 30, 2025 | 8.42% |
| Mar 31, 2025 | -5.35% |
| Dec 31, 2024 | 5.84% |
| Sep 30, 2024 | 7.06% |
| Jun 30, 2024 | -281.76% |
| Mar 31, 2024 | 18.96% |
| Dec 31, 2023 | 17.05% |
| Sep 30, 2023 | 15.76% |
| Jun 30, 2023 | 3.03% |
| Mar 31, 2023 | 5.10% |
| Dec 31, 2022 | 11.98% |
| Sep 30, 2022 | 152.91% |
| Jun 30, 2022 | 44.72% |
| Mar 31, 2022 | 41.56% |
| Dec 31, 2021 | -20.81% |
| Sep 30, 2021 | 87.74% |